← Back to Search

Treatment D: BMS-986419 Crushed IR Tablet - Fed for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 29 days
Awards & highlights

Study Summary

This trial studies the effects of a new tablet version vs. a capsule version of a drug on healthy adults, and how food affects the drug levels of the tablet.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 29 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 29 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])
Maximum observed plasma concentration (Cmax)
Secondary outcome measures
Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24))
Number of participants with adverse events (AEs)
Number of participants with clinical laboratory abnormalities
+5 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Treatment D: BMS-986419 Crushed IR Tablet - FedExperimental Treatment1 Intervention
Group II: Treatment C: BMS-986419 IR Tablet - FedExperimental Treatment1 Intervention
Group III: Treatment B: BMS-986419 IR Tablet - FastedExperimental Treatment1 Intervention
Group IV: Treatment A: BMS-986419 DR Capsule - FastedExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986419 DR Capsule
2023
Completed Phase 1
~60
BMS-986419 IR Tablet
2023
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,638 Previous Clinical Trials
4,128,454 Total Patients Enrolled

Media Library

Treatment D: BMS-986419 Crushed IR Tablet - Fed Clinical Trial Eligibility Overview. Trial Name: NCT05963932 — Phase 1
Healthy Subjects Research Study Groups: Treatment D: BMS-986419 Crushed IR Tablet - Fed, Treatment B: BMS-986419 IR Tablet - Fasted, Treatment C: BMS-986419 IR Tablet - Fed, Treatment A: BMS-986419 DR Capsule - Fasted
Healthy Subjects Clinical Trial 2023: Treatment D: BMS-986419 Crushed IR Tablet - Fed Highlights & Side Effects. Trial Name: NCT05963932 — Phase 1
Treatment D: BMS-986419 Crushed IR Tablet - Fed 2023 Treatment Timeline for Medical Study. Trial Name: NCT05963932 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Will my profile match the criteria for this medical trial?

"To be considered for this experiment, potential candidates must fall between 18 and 55 years old and have no serious medical conditions. The recruitment process is looking to secure 60 participants in total."

Answered by AI

What is the total number of individuals enrolled in this research endeavor?

"Affirmative. Clinicaltrials.gov displays that this clinical study, which was first advertised on August 8th 2023, is actively seeking participants. Approximately 60 individuals are required for the trial at a single site."

Answered by AI

What risks have been associated with administering the BMS-986419 Crushed IR Tablet - Fed to patients?

"As Treatment D: BMS-986419 Crushed IR Tablet - Fed is in the early stages of clinical trials, there is limited data supporting its safety and efficacy -- therefore our team assigned it a score of 1 on our scale."

Answered by AI

Does this research offer opportunities for individuals over fifty years of age?

"To qualify for this clinical trial, the patient must be between 18 and 55 years of age. In contrast, 57 trials are available to younger patients while 388 studies target an elderly demographic."

Answered by AI

Are there opportunities to join the study at this time?

"According to records on clinicaltrials.gov, the recruitment process for this medical trial remains ongoing since its initial posting on August 8th 2023 and most recent edit from 28th of that same month."

Answered by AI

Who else is applying?

What site did they apply to?
Anaheim Clinical Trials
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants
2023. "A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05963932.
~36 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top